Navigation Links
Cholesterol Drug Found To Slow Alzheimer’s Progressio

New research shows that cholesterol-lowering drugs may slow mental decline and improve symptoms of depression in Alzheimer’s patients. //

A small pilot study was conducted to test the drug on patients with mild to moderate Alzheimer’s disease . 46 patients were followed for one year, twenty-five of the patients took the cholesterol-lowering drug, and the remaining 21 patients received a placebo. All of the patients in the study also took cholinesterase inhibitors, which are the only FDA-approved drugs for mild to moderate Alzheimer’s.

Previous studies have shown that high cholesterol is a risk factor for Alzheimer’s disease. Results from this study showed that more than 50 percent of patients who took the cholesterol-lowering drug improved their mental state or stayed the same after one year and only 28 percent of those in the placebo group improved or stayed the same. Patients on the cholesterol-lowering drug also showed a significant improvement in their symptoms of depression, while those who did not take the drug showed a decline.

Thus researchers say the findings of their study are important because the data showed that cholesterol-lowering treatment works in excess of the only currently approved therapy for Alzheimer’s disease. However researchers say further research is required to confirm the above findings
'"/>




Page: 1

Related medicine news :

1. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
2. Eating More Often May Help Lower Cholesterol
3. Caution On Use of Cholesterol Drugs
4. High Cholesterol linked to Alzheimer’s diseas
5. Cholesterol Drug Helps After Angioplasty
6. Cholesterol lowering drugs increase neuropathy risk
7. Almonds Improve Cholesterol
8. Cholesterol-lowering therapy benefits older people also
9. Cholesterol lowering drugs aid people after heart transplant
10. New Cholesterol gene linked to Alzheimers
11. Children’s Cholesterol Matter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today ... Christopher Gabrieli , partner emeritus ... of the board of Akcea Therapeutics. ... Sandford D. Smith , founder and ... are excited to announce this expansion to our board and ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
Breaking Medicine Technology: